{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:27:21Z","timestamp":1783603641193,"version":"3.55.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The 2024 Healthcare Quality (Evidence-Based) Management Research Project of the National Institute of Hospital Administration, National Medical Commission of the People's Republic of China","award":["No.YLZLXZ24G030"],"award-info":[{"award-number":["No.YLZLXZ24G030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40263-025-01220-5","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:41:36Z","timestamp":1756464096000},"page":"1297-1315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Plasma Protein Patterns Associated with Paliperidone Palmitate Maintenance Therapy in Schizophrenia: A Prospective Cohort Study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-7087","authenticated-orcid":false,"given":"Weiwei","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiqing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-2714","authenticated-orcid":false,"given":"HaiBin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"9162","key":"1220_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(98)07549-7","volume":"353","author":"SK Schultz","year":"1999","unstructured":"Schultz SK, Andreasen NC. Schizophrenia. Lancet. 1999;353(9162):1425\u201330.","journal-title":"Lancet"},{"key":"1220_CR2","unstructured":"Institute of Health Metrics and Evaluation (IHME). Global Health Data Exchange (GHDx). http:\/\/ghdx.healthdata.org\/gbd-results-tool?params=gbd-api-2019"},{"issue":"3","key":"1220_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2215-0366(18)30511-X","volume":"6","author":"Y Huang","year":"2019","unstructured":"Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211\u201324.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"1220_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195\u2013203.","journal-title":"Schizophr Bull"},{"issue":"12","key":"1220_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatr. 2015;72(12):1172\u201381.","journal-title":"JAMA Psychiatr"},{"issue":"6","key":"1220_CR6","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2020.106","volume":"6","author":"MS Ran","year":"2020","unstructured":"Ran MS, Xiao Y, Fazel S, et al. Mortality and suicide in schizophrenia: 21-year follow-up in rural China. BJPsych Open. 2020;6(6): e121.","journal-title":"BJPsych Open"},{"key":"1220_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.schres.2022.12.004","volume":"251","author":"N Bareis","year":"2023","unstructured":"Bareis N, Olfson M, Gerhard T, et al. Means of suicide among adults with schizophrenia across the life span. Schizophr Res. 2023;251:82\u201390.","journal-title":"Schizophr Res"},{"issue":"3","key":"1220_CR8","first-page":"201","volume":"44","author":"SM Mothershed","year":"1968","unstructured":"Mothershed SM, Bullard JC. Preparation of fluorescein-labelled immune globulin for the identification of Treponema pallidum. Br J Vener Dis. 1968;44(3):201\u20137.","journal-title":"Br J Vener Dis"},{"key":"1220_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.08.016","volume":"131","author":"FC Nucifora Jr.","year":"2019","unstructured":"Nucifora FC Jr., Woznica E, Lee BJ, et al. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131: 104257.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"1220_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12325-013-0016-5","volume":"30","author":"S Offord","year":"2013","unstructured":"Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;30(3):286\u201397.","journal-title":"Adv Ther"},{"issue":"9","key":"1220_CR11","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41380-023-02175-z","volume":"28","author":"L Boyer","year":"2023","unstructured":"Boyer L, Falissard B, Nuss P, et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023;28(9):3709\u201316.","journal-title":"Mol Psychiatry"},{"key":"1220_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380.","journal-title":"Schizophr Res"},{"issue":"7","key":"1220_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatr. 2017;74(7):686\u201393.","journal-title":"JAMA Psychiatr"},{"issue":"8","key":"1220_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40263-025-01194-4","volume":"39","author":"Q Li","year":"2025","unstructured":"Li Q, Li Y, Yang Y, et al. Efficacy and safety of once-monthly paliperidone palmitate long-acting injections in Chinese patients with early-, mid-, and late-phase schizophrenia: a post-hoc analysis of three phase 4 studies. CNS Drugs. 2025;39(8):795\u2013805.","journal-title":"CNS Drugs"},{"key":"1220_CR15","doi-asserted-by":"publisher","first-page":"1501701","DOI":"10.3389\/fphar.2025.1501701","volume":"16","author":"R Liu","year":"2025","unstructured":"Liu R, Liu C, Hu D, et al. An analysis of the clinical application of paliperidone palmitate injection based on real-world. Front Pharmacol. 2025;16:1501701.","journal-title":"Front Pharmacol"},{"key":"1220_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.schres.2017.01.002","volume":"185","author":"Z Bai","year":"2017","unstructured":"Bai Z, Wang G, Cai S, et al. Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis. Schizophr Res. 2017;185:73\u20139.","journal-title":"Schizophr Res"},{"issue":"8","key":"1220_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatr. 2015;72(8):830\u20139.","journal-title":"JAMA Psychiatr"},{"issue":"9896","key":"1220_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"5","key":"1220_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4331\/wjbc.v12.i5.57","volume":"12","author":"S Al-Amrani","year":"2021","unstructured":"Al-Amrani S, Al-Jabri Z, Al-Zaabi A, et al. Proteomics: concepts and applications in human medicine. World J Biol Chem. 2021;12(5):57\u201369.","journal-title":"World J Biol Chem"},{"key":"1220_CR20","doi-asserted-by":"publisher","unstructured":"Chandramouli K, Qian PY. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics 2009 Dec 8;2009:239204. https:\/\/doi.org\/10.4061\/2009\/239204.","DOI":"10.4061\/2009\/239204"},{"key":"1220_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2016.00018","volume":"10","author":"K Davalieva","year":"2016","unstructured":"Davalieva K, Maleva Kostovska I, Dwork AJ. Proteomics research in schizophrenia. Front Cell Neurosci. 2016;10: 18.","journal-title":"Front Cell Neurosci"},{"issue":"10","key":"1220_CR22","first-page":"1704","volume":"57","author":"X Ren","year":"2023","unstructured":"Ren X, Tan SM, Liu JX, et al. Research progress of transcriptomics and proteomics in schizophrenia. Zhonghua Yu Fang Yi Xue Za Zhi. 2023;57(10):1704\u201310.","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"1220_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/B978-0-12-813176-3.00025-0","volume-title":"Personalized Psychiatry","author":"DR Cotter","year":"2020","unstructured":"Cotter DR, Sabherwal S, Schubert KO. Chapter 25 - Proteomics for diagnostic and therapeutic blood biomarker discovery in schizophrenia and other psychotic disorders. In: Baune BT, editor. Personalized Psychiatry. San Diego: Academic Press; 2020. p. 307\u201317."},{"key":"1220_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091408","author":"BJ Smith","year":"2022","unstructured":"Smith BJ, Brand\u00e3o-Teles C, Zuccoli GS, et al. Protein succinylation and malonylation as potential biomarkers in schizophrenia. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12091408.","journal-title":"J Pers Med"},{"key":"1220_CR25","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13907","volume":"10","author":"E Dmitrieva","year":"2022","unstructured":"Dmitrieva E, Smirnova L, Seregin A, et al. Proteomic profile of serum from patients with schizophrenia spectrum disorders. PeerJ. 2022;10: e13907.","journal-title":"PeerJ"},{"key":"1220_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jpsychires.2023.11.031","volume":"169","author":"H Lee","year":"2024","unstructured":"Lee H, Kim M, Kim SH, et al. Proteomic profiling in the progression of psychosis: analysis of clinical high-risk, first episode psychosis, and healthy controls. J Psychiatr Res. 2024;169:264\u201371.","journal-title":"J Psychiatr Res"},{"key":"1220_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094917","author":"JE Rodrigues","year":"2022","unstructured":"Rodrigues JE, Martinho A, Santa C, et al. Systematic review and meta-analysis of mass spectrometry proteomics applied to human peripheral fluids to assess potential biomarkers of schizophrenia. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23094917.","journal-title":"Int J Mol Sci"},{"key":"1220_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2024.104059","volume":"3","author":"C Pisanu","year":"2024","unstructured":"Pisanu C, Severino G, Minelli A, et al. Biomarkers of treatment-resistant schizophrenia: a systematic review. Neuroscience Applied. 2024;3: 104059.","journal-title":"Neuroscience Applied"},{"issue":"6","key":"1220_CR29","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41380-018-0058-9","volume":"24","author":"T Pillinger","year":"2019","unstructured":"Pillinger T, D\u2019Ambrosio E, McCutcheon R, et al. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24(6):776\u201394.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"1220_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/wps.20069","volume":"12","author":"D Vancampfort","year":"2013","unstructured":"Vancampfort D, Wampers M, Mitchell AJ, et al. A meta-analysis of cardio-metabolic abnormalities in drug na\u00efve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240\u201350.","journal-title":"World Psychiatry"},{"issue":"5","key":"1220_CR31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bdi.12505","volume":"19","author":"M Strassnig","year":"2017","unstructured":"Strassnig M, Kotov R, Cornaccio D, et al. Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. Bipolar Disord. 2017;19(5):336\u201343.","journal-title":"Bipolar Disord"},{"issue":"4","key":"1220_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40263-013-0054-1","volume":"27","author":"G Scigliano","year":"2013","unstructured":"Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249\u201357.","journal-title":"CNS Drugs"},{"key":"1220_CR33","unstructured":"Xiaodong Peng H X HZ, Dong Jin, et al. Epidemiological features of severe mental disorders of Shenzhen in 2017. Modern Preventive Med. 2018;45(05): 777-80+88."},{"issue":"Suppl 1","key":"1220_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","volume":"75","author":"S Leucht","year":"2014","unstructured":"Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75(Suppl 1):8\u201314.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1220_CR35","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41591-019-0673-2","volume":"25","author":"B Lehallier","year":"2019","unstructured":"Lehallier B, Gate D, Schaum N, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med. 2019;25(12):1843\u201350.","journal-title":"Nat Med"},{"issue":"6","key":"1220_CR36","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1038\/s41380-023-02104-0","volume":"28","author":"Y Yu","year":"2023","unstructured":"Yu Y, Fu Y, Yu Y, et al. Investigating the shared genetic architecture between schizophrenia and body mass index. Mol Psychiatry. 2023;28(6):2312\u20139.","journal-title":"Mol Psychiatry"},{"key":"1220_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116220","volume":"342","author":"Z Sarnyai","year":"2024","unstructured":"Sarnyai Z, Ben-Shachar D. Schizophrenia, a disease of impaired dynamic metabolic flexibility: a new mechanistic framework. Psychiatry Res. 2024;342: 116220.","journal-title":"Psychiatry Res"},{"issue":"10","key":"1220_CR38","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJM199403103301006","volume":"330","author":"WT Carpenter Jr","year":"1994","unstructured":"Carpenter WT Jr, Buchanan RW. Schizophrenia. N Engl J Med. 1994;330(10):681\u201390.","journal-title":"N Engl J Med"},{"issue":"4","key":"1220_CR39","first-page":"561","volume":"25","author":"SB Wang","year":"2024","unstructured":"Wang SB, Tan W, Fu XY. The use and evaluation of long-acting injectable antipsychotic medications in community-dwelling patients with schizophrenia in Guangdong province, China. Alpha Psychiatr. 2024;25(4):561\u20133.","journal-title":"Alpha Psychiatr"},{"issue":"5","key":"1220_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"1220_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ddr.21337","volume":"77","author":"NP Maric","year":"2016","unstructured":"Maric NP, Jovicic MJ, Mihaljevic M, et al. Improving current treatments for schizophrenia. Drug Dev Res. 2016;77(7):357\u201367.","journal-title":"Drug Dev Res"},{"issue":"6","key":"1220_CR42","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/jpm.13075","volume":"31","author":"CTC Okoli","year":"2024","unstructured":"Okoli CTC, Abufarsakh B, Wang T, et al. Assessing the impact of long-acting injectable compared to oral antipsychotic medications on readmission to a state psychiatric hospital. J Psychiatr Ment Health Nurs. 2024;31(6):1155\u201363.","journal-title":"J Psychiatr Ment Health Nurs"},{"issue":"5","key":"1220_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","volume":"35","author":"D Lin","year":"2021","unstructured":"Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469\u201381.","journal-title":"CNS Drugs"},{"issue":"4","key":"1220_CR44","first-page":"261","volume":"2","author":"J Kantrowitz","year":"2008","unstructured":"Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evid. 2008;2(4):261\u201371.","journal-title":"Core Evid"},{"issue":"2","key":"1220_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.64719\/pb.4361","volume":"47","author":"MT Morris","year":"2017","unstructured":"Morris MT, Tarpada SP. Long-acting injectable paliperidone palmitate: a review of efficacy and safety. Psychopharmacol Bull. 2017;47(2):42\u201352.","journal-title":"Psychopharmacol Bull"},{"key":"1220_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/NDT.S139633","volume":"14","author":"R Emsley","year":"2018","unstructured":"Emsley R, Kilian S. Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatr Dis Treat. 2018;14:205\u201323.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"1220_CR47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/neurolint13030035","volume":"13","author":"HD Minwalla","year":"2021","unstructured":"Minwalla HD, Wrzesinski P, Desforges A, et al. Paliperidone to treat psychotic disorders. Neurol Int. 2021;13(3):343\u201358.","journal-title":"Neurol Int"},{"issue":"3","key":"1220_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF02251280","volume":"110","author":"S Nyberg","year":"1993","unstructured":"Nyberg S, Farde L, Eriksson L, et al. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology. 1993;110(3):265\u201372.","journal-title":"Psychopharmacology"},{"issue":"8","key":"1220_CR49","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","volume":"160","author":"RA Bressan","year":"2003","unstructured":"Bressan RA, Erlandsson K, Jones HM, et al. Is regionally selective D2\/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry. 2003;160(8):1413\u201320.","journal-title":"Am J Psychiatry"},{"issue":"Suppl","key":"1220_CR50","first-page":"5","volume":"55","author":"JE Leysen","year":"1994","unstructured":"Leysen JE, Janssen PM, Megens AA, et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55(Suppl):5\u201312.","journal-title":"J Clin Psychiatry"},{"key":"1220_CR51","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.2147\/NDT.S142634","volume":"13","author":"R Emsley","year":"2017","unstructured":"Emsley R, Hargarter L, Bergmans P, et al. Once-monthly paliperidone palmitate in early stage schizophrenia\u2014a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatr Dis Treat. 2017;13:2261\u20139.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"1220_CR52","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","volume":"62","author":"SR Marder","year":"2007","unstructured":"Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363\u201370.","journal-title":"Biol Psychiatry"},{"issue":"1\u20133","key":"1220_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1\u20133):147\u201361.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"1220_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","volume":"93","author":"M Davidson","year":"2007","unstructured":"Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1\u20133):117\u201330.","journal-title":"Schizophr Res"},{"issue":"5","key":"1220_CR55","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","volume":"20","author":"J Horacek","year":"2006","unstructured":"Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389\u2013409.","journal-title":"CNS Drugs"},{"key":"1220_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.brainres.2008.07.021","volume":"1233","author":"P Corena-McLeod Mdel","year":"2008","unstructured":"Corena-McLeod Mdel P, Oliveros A, Charlesworth C, et al. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res. 2008;1233:8\u201319.","journal-title":"Brain Res"},{"issue":"11","key":"1220_CR57","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s12264-021-00740-6","volume":"37","author":"Q Wu","year":"2021","unstructured":"Wu Q, Wang X, Wang Y, et al. Developments in biological mechanisms and treatments for negative symptoms and cognitive dysfunction of schizophrenia. Neurosci Bull. 2021;37(11):1609\u201324.","journal-title":"Neurosci Bull"},{"issue":"8","key":"1220_CR58","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","volume":"5","author":"S Galderisi","year":"2018","unstructured":"Galderisi S, Mucci A, Buchanan RW, et al. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664\u201377.","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"1220_CR59","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40263-023-01028-1","volume":"37","author":"Q Li","year":"2023","unstructured":"Li Q, Li X, Ye C, et al. Effectiveness and safety of switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M) in the management of schizophrenia: a systematic review and meta-analysis. CNS Drugs. 2023;37(8):695\u2013713.","journal-title":"CNS Drugs"},{"issue":"3","key":"1220_CR60","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4088\/JCP.14m09416","volume":"76","author":"DJ Fu","year":"2015","unstructured":"Fu DJ, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015;76(3):253\u201362.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"1220_CR61","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1185\/03007995.2012.708327","volume":"28","author":"M Schmauss","year":"2012","unstructured":"Schmauss M, Juki\u0107 V, Siracusano A, et al. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Curr Med Res Opin. 2012;28(8):1395\u2013404.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1220_CR62","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/npp.2010.79","volume":"35","author":"HA Nasrallah","year":"2010","unstructured":"Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072\u201382.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1220_CR63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S2215-0366(23)00005-6","volume":"10","author":"I Winter-van Rossum","year":"2023","unstructured":"Winter-van Rossum I, Weiser M, Galderisi S, et al. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry. 2023;10(3):197\u2013208.","journal-title":"Lancet Psychiatry"},{"key":"1220_CR64","unstructured":"FDA. Label: INVEGA SUSTENNA (paliperidone palmitate) 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022264s023lbl.pdf."},{"issue":"1","key":"1220_CR65","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64\u201377.","journal-title":"Lancet Psychiatry"},{"key":"1220_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030238","author":"M Carli","year":"2021","unstructured":"Carli M, Kolachalam S, Longoni B, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14030238.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"1220_CR67","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1172\/JCI93362","volume":"127","author":"CC Lord","year":"2017","unstructured":"Lord CC, Wyler SC, Wan R, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017;127(9):3402\u20136.","journal-title":"J Clin Invest"},{"issue":"1","key":"1220_CR68","first-page":"32","volume":"49","author":"T Si","year":"2016","unstructured":"Si T, Fan J, Wang X, et al. A subgroup analysis of Chinese patients switched to paliperidone palmitate one-month injectable by prior oral antipsychotic treatment. Pharmacopsychiatry. 2016;49(1):32\u201341.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"1220_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.schres.2011.06.016","volume":"132","author":"JK Sliwa","year":"2011","unstructured":"Sliwa JK, Bossie CA, Ma YW, et al. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res. 2011;132(1):28\u201334.","journal-title":"Schizophr Res"},{"issue":"1","key":"1220_CR70","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12864-024-10412-0","volume":"25","author":"Z Cao","year":"2024","unstructured":"Cao Z, Li Q, Li Y, et al. Identification of plasma protein markers of allergic disease risk: a mendelian randomization approach to proteomic analysis. BMC Genomics. 2024;25(1):503.","journal-title":"BMC Genomics"},{"issue":"6","key":"1220_CR71","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1038\/s41380-020-00993-z","volume":"26","author":"X Song","year":"2021","unstructured":"Song X, Chen X, Yuksel C, et al. Bioenergetics and abnormal functional connectivity in psychotic disorders. Mol Psychiatry. 2021;26(6):2483\u201392.","journal-title":"Mol Psychiatry"},{"key":"1220_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.847611","volume":"13","author":"D Zhen","year":"2022","unstructured":"Zhen D, Liu J, Zhang XD, et al. Kynurenic acid acts as a signaling molecule regulating energy expenditure and is closely associated with metabolic diseases. Front Endocrinol (Lausanne). 2022;13: 847611.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1220_CR73","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12974-024-03253-x","volume":"21","author":"YY Lin","year":"2024","unstructured":"Lin YY, Chang WH, Hsieh SL, et al. The deficient CLEC5A ameliorates the behavioral and pathological deficits via the microglial A\u03b2 clearance in Alzheimer\u2019s disease mouse model. J Neuroinflammation. 2024;21(1):273.","journal-title":"J Neuroinflammation"},{"issue":"8","key":"1220_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.170","volume":"7","author":"H Kimura","year":"2017","unstructured":"Kimura H, Fujita Y, Kawabata T, et al. A novel rare variant R292H in RTN4R affects growth cone formation and possibly contributes to schizophrenia susceptibility. Transl Psychiatry. 2017;7(8): e1214.","journal-title":"Transl Psychiatry"},{"issue":"4","key":"1220_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002655","volume":"8","author":"ST Chen","year":"2012","unstructured":"Chen ST, Liu RS, Wu MF, et al. CLEC5A regulates Japanese encephalitis virus-induced neuroinflammation and lethality. PLoS Pathog. 2012;8(4): e1002655.","journal-title":"PLoS Pathog"},{"key":"1220_CR76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pnpbp.2011.11.003","volume":"42","author":"U Meyer","year":"2013","unstructured":"Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:20\u201334.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1220_CR77","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fncel.2015.00180","volume":"9","author":"PC Guest","year":"2015","unstructured":"Guest PC, Iwata K, Kato TA, et al. MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia. Front Cell Neurosci. 2015;9:180.","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"1220_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/gbb.12719","volume":"20","author":"T Yamauchi","year":"2021","unstructured":"Yamauchi T, Kang G, Hiroi N. Heterozygosity of murine Crkl does not recapitulate behavioral dimensions of human 22q11.2 hemizygosity. Genes Brain Behav. 2021;20(5): e12719.","journal-title":"Genes Brain Behav"},{"issue":"6","key":"1220_CR79","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.biopsych.2013.03.018","volume":"74","author":"J Flatow","year":"2013","unstructured":"Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74(6):400\u20139.","journal-title":"Biol Psychiatry"},{"key":"1220_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12040975","author":"G De Simone","year":"2023","unstructured":"De Simone G, Mazza B, Vellucci L, et al. Schizophrenia synaptic pathology and antipsychotic treatment in the framework of oxidative and mitochondrial dysfunction: translational highlights for the clinics and treatment. Antioxidants. 2023. https:\/\/doi.org\/10.3390\/antiox12040975.","journal-title":"Antioxidants"},{"issue":"6","key":"1220_CR81","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/01.STR.0000128416.28778.7a","volume":"35","author":"A Saito","year":"2004","unstructured":"Saito A, Hayashi T, Okuno S, et al. Oxidative stress is associated with XIAP and Smac\/DIABLO signaling pathways in mouse brains after transient focal cerebral ischemia. Stroke. 2004;35(6):1443\u20138.","journal-title":"Stroke"},{"key":"1220_CR82","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1196\/annals.1338.022","volume":"1042","author":"PH Chan","year":"2005","unstructured":"Chan PH. Mitochondrial dysfunction and oxidative stress as determinants of cell death\/survival in stroke. Ann N Y Acad Sci. 2005;1042:203\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"1220_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176910","volume":"12","author":"NA Rivero-Segura","year":"2017","unstructured":"Rivero-Segura NA, Flores-Soto E, Garc\u00eda de la Cadena S, et al. Prolactin-induced neuroprotection against glutamate excitotoxicity is mediated by the reduction of [Ca2+]i overload and NF-\u03baB activation. PLoS ONE. 2017;12(5): e0176910.","journal-title":"PLoS ONE"},{"key":"1220_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ebiom.2016.03.048","volume":"7","author":"R Mel\u00e9ndez Garc\u00eda","year":"2016","unstructured":"Mel\u00e9ndez Garc\u00eda R, Arredondo Zamarripa D, Arnold E, et al. Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death. EBioMedicine. 2016;7:35\u201349.","journal-title":"EBioMedicine"},{"key":"1220_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071418","author":"M Stojkovic","year":"2024","unstructured":"Stojkovic M, Jovanovic M, Jakovljevic V, et al. Protective effect of hyperprolactinemia on oxidative stress in patients with psychotic disorder on atypical antipsychotics risperidone and paliperidone: a cross-sectional study. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12071418.","journal-title":"Biomedicines"},{"issue":"1","key":"1220_CR86","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41467-017-00356-3","volume":"8","author":"ST Chen","year":"2017","unstructured":"Chen ST, Li FJ, Hsu TY, et al. CLEC5A is a critical receptor in innate immunity against Listeria infection. Nat Commun. 2017;8(1):299.","journal-title":"Nat Commun"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01220-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:05:10Z","timestamp":1762884310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01220-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":86,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01220-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"We commit that any researcher with a legitimate request for the data can access it under strict privacy protection and data usage agreements. Researchers interested in obtaining the data must submit a methodologically sound research proposal to the corresponding author and may access the data upon approval. Our aim is to promote validation and application of these findings within the scientific community through responsible data sharing, while ensuring participant privacy and data security.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This clinical cohort study has obtained ethical approval from the Ethics Committee of Longgang Second People\u2019s Hospital in Shenzhen, with approval number LGEY-IRB-KY-2024-001. The study strictly adhered to the Declaration of Helsinki and all applicable ethical guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The present work and its open access publication were funded by The 2024 Healthcare Quality (Evidence-Based) Management Research Project of the National Institute of Hospital Administration, National Medical Commission of the People's Republic of China (No. YLZLXZ24G030). The sponsors of the study had no role in study design, data collection, analysis, interpretation, or writing of the report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All participants received comprehensive study information and provided written informed consent prior to enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"W.W. Zeng was conceived the study, result interpretation; made significant revisions to the manuscript\u2019s content and involved in funding acquisition and research supervision.Tahir Ali and H.B. Dai made significant revisions to the manuscript's content. F.Q. Liang conceived the study, participated in PANSS scale assessment, data collection, data analysis, result interpretation, and drafted the manuscript. X.Y. Lin participated in sample processing and manuscript writing. Y.Y. Zhang also participated in PANSS scale assessment. Y.Z. Zheng participated in sample collection, data collection and andobtained informed consent. All authors participated in the discussion of results and provided input for the paper publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship Contributions"}}]}}